Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype

被引:114
|
作者
Weber, J
Fenyo, EM
Beddows, S
Kaleebu, P
Bjorndal, A
Osmanov, S
Heyward, W
Esparza, J
GalvaoCastro, B
vandePerre, P
Karita, E
Wasi, C
Sempala, S
Tugume, B
Biryahwaho, B
RubsamenWaigmann, H
vonBriesen, H
Esser, R
Grez, M
Holmes, H
Newberry, A
Ranjbar, S
Tomlinson, P
Bradac, J
McCutchan, F
Louwagie, J
Hegerich, P
LopezGalindez, C
Olivares, I
Dopazo, J
Mullins, JI
Delwart, EL
Bachmann, HM
Goudsmit, J
deWolf, F
Hahn, BH
Gao, F
Yue, L
Saragosti, S
Schochetman, G
Kalish, M
Luo, CC
George, R
Pau, CP
CheingsongPopov, R
Nara, P
Albert, J
Myers, G
Korber, B
机构
[1] KAROLINSKA INST,MICROBIOL & TUMOUR BIOL CTR,S-10401 STOCKHOLM,SWEDEN
[2] WHO,GLOBAL PROGRAMME AIDS,CH-1211 GENEVA,SWITZERLAND
[3] OSWALDO CRUZ FDN,SALVADOR,BA,BRAZIL
[4] NATL HIV AIDS REFERENCE LAB,KIGALI,RWANDA
[5] MAHIDOL UNIV,DEPT MICROBIOL,BANGKOK 10700,THAILAND
[6] UGANDA VIRUS RES INST,ENTEBBE,UGANDA
[7] GEORG SPEYER HAUS CHEMOTHERAPEUT FORSCHUNGSINST,FRANKFURT,GERMANY
[8] NATL INST BIOL STAND & CONTROLS,LONDON NW3 6RB,ENGLAND
[9] NIAID,DIV AIDS,BETHESDA,MD 20892
[10] WALTER REED ARMY INST RES,HENRY M JACKSON FDN LAB,ROCKVILLE,MD
[11] INST SALUD CARLOS III,CTR NACL BIOL CELULAR & RETROVIRUS,MADRID,SPAIN
[12] STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305
[13] UNIV AMSTERDAM,ACAD MED CTR,HUMAN RETROVIRUS LAB,NL-1105 AZ AMSTERDAM,NETHERLANDS
[14] UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294
[15] INST COCHIN,PARIS,FRANCE
[16] CTR DIS CONTROL & PREVENT,ATLANTA,GA 30333
[17] ST MARYS HOSP,SCH MED,LONDON,ENGLAND
[18] NCI,VIRUS BIOL UNIT,FREDERICK,MD 21701
[19] SWEDISH INST INFECT DIS CONTROL,STOCKHOLM,SWEDEN
[20] LOS ALAMOS NATL LAB,LOS ALAMOS,NM 87545
关键词
D O I
10.1128/JVI.70.11.7827-7832.1996
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type 1 (HIV-1) primary isolates from four geographical locations in Thailand, Brazil, Rwanda, and Uganda, representing genetic subtypes A, B, C, D, and E, were examined for autologous and heterologous neutralization by panels of human HIV+ polyclonal plasma. In independent linked experiments in three laboratories using diverse methodologies and common reagents, no defined pattern of genetic subtype-specific neutralization was observed. Most plasma tested were broadly cross-neutralizing across two or more genetic subtypes, although the titer of neutralization varied across a wide range. We conclude that the genetic subtypes of HIV-1 are not classical neutralization serotypes.
引用
收藏
页码:7827 / 7832
页数:6
相关论文
共 50 条
  • [31] THE PRINCIPAL NEUTRALIZATION DETERMINANT OF SIMIAN IMMUNODEFICIENCY VIRUS DIFFERS FROM THAT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    JAVAHERIAN, K
    LANGLOIS, AJ
    SCHMIDT, S
    KAUFMANN, M
    CATES, N
    LANGEDIJK, JPM
    MELOEN, RH
    DESROSIERS, RC
    BURNS, DPW
    BOLOGNESI, DP
    LAROSA, GJ
    PUTNEY, SD
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (04) : 1418 - 1422
  • [32] CHARACTERIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES FROM CHILDREN IN ROMANIA - IDENTIFICATION OF A NEW ENVELOPE SUBTYPE
    DUMITRESCU, O
    KALISH, ML
    KLIKS, SC
    BANDEA, CI
    LEVY, JA
    JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (02): : 281 - 288
  • [33] IMMUNOGLOBULIN A-MEDIATED NEUTRALIZATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    BURNETT, PR
    POLONIS, V
    VANCOTT, TC
    BIRX, DL
    REDFIELD, RR
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 : S34 - S34
  • [34] Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity
    LaCasse, RA
    Follis, KE
    Moudgil, T
    Trahey, M
    Binley, JM
    Planelles, V
    Zolla-Pazner, S
    Nunberg, JH
    JOURNAL OF VIROLOGY, 1998, 72 (03) : 2491 - 2495
  • [35] Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization
    Yang, Xinzhen
    Lipchina, Inna
    Cocklin, Simon
    Chaiken, Irwin
    Sodroski, Joseph
    JOURNAL OF VIROLOGY, 2006, 80 (22) : 11404 - 11408
  • [36] Travel and the introduction of human immunodeficiency virus type 1 non-B subtype genetic forms into western countries
    Thomson, MM
    Nájera, R
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (12) : 1732 - 1737
  • [37] A microassay for determination of the cytopathogenicity of human immunodeficiency virus type-1 isolates
    Benyoucef, S
    Hober, D
    Shen, L
    Ajana, F
    Gerard, Y
    BocketMouton, L
    Mouton, Y
    Wattre, P
    MICROBIOLOGY AND IMMUNOLOGY, 1996, 40 (05) : 381 - 388
  • [38] Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
    Bures, R
    Morris, L
    Williamson, C
    Ramjee, G
    Deers, M
    Fiscus, SA
    Abdool Karim, SS
    Montefiori, DC
    JOURNAL OF VIROLOGY, 2002, 76 (05) : 2233 - 2244
  • [39] Cross-Subtype Neutralization Sensitivity despite Monoclonal Antibody Resistance among Early Subtype A, C, and D Envelope Variants of Human Immunodeficiency Virus Type 1
    Blish, Catherine A.
    Jalalian-Lechak, Zahra
    Rainwater, Stephanie
    Nguyen, Minh-An
    Dogan, Ozge C.
    Overbaugh, Julie
    JOURNAL OF VIROLOGY, 2009, 83 (15) : 7783 - 7788
  • [40] The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope
    Gorny, MK
    Revesz, K
    Williams, C
    Volsky, B
    Louder, MK
    Anyangwe, CA
    Krachmarov, C
    Kayman, SC
    Pinter, A
    Nadas, A
    Nyambi, PN
    Mascola, JR
    Zolla-Pazner, S
    JOURNAL OF VIROLOGY, 2004, 78 (05) : 2394 - 2404